This HTML5 document contains 207 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://dx.doi.org/10.1093/NEUONC/
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34480689
rdf:type
wikibase:Item
schema:description
vědecký článek artículo científico publicado en 2010 vetenskaplig artikel vedecký článok 2010年论文 מאמר מדעי научная статья mokslinis straipsnis wetenschappelijk artikel artikull shkencor artigo científico (publicado na 2010) 2010年论文 مقالهٔ علمی teaduslik artikkel scienca artikolo 2010年論文 videnskabelig artikel (udgivet 2010) ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scientific article bài báo khoa học article científic wissenschaftlicher Artikel 2010 nî lūn-bûn 2010年论文 2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած 2010年論文 vitskapeleg artikkel artigo científico articol științific научни чланак επιστημονικό άρθρο мақолаи илмӣ სამეცნიერო სტატია мақолаи илмӣ 2010年论文 tudományos cikk bilimsel makale articolo scientifico наукова стаття, опублікована в серпні 2010 vitenskapelig artikkel سائنسی مضمون научна статия artykuł naukowy artículu científicu espublizáu en 2010 artigo científico (publicado na 2010) научни чланак 2010 թվականի օգոստոսին հրատարակված գիտական հոդված 2010年論文 2010년 논문 artikulong pang-agham مقالة علمية บทความทางวิทยาศาสตร์ 2010年论文 article scientific 2010年论文 2010年論文 naučni članak 2010年論文 2010年の論文 article scientifique (publié 2010) tieteellinen artikkeli
p:P577
wds:Q34480689-7F72FAE6-0799-45BE-A913-D4A2A3B431D1
wdt:P577
2010-08-17T00:00:00Z
p:P2860
wds:Q34480689-93256DA0-0779-4969-8E42-7375D10510CD wds:Q34480689-96ADEFAC-8585-448B-A03D-C26D7B146F43 wds:Q34480689-9F4EA4B8-CD96-4783-AF9C-06D15D174E0A wds:Q34480689-9FABD214-6627-42BF-9116-0EF7ED8B4910 wds:Q34480689-7F34CB9B-FAD4-4260-A842-3E888A642007 wds:Q34480689-FA5366DF-3529-4838-9C09-201BA673C8DA wds:Q34480689-FBDC9092-CA17-4385-AD2C-E9595D260ADB wds:Q34480689-FD4E5377-B03E-445B-A1F8-48977C77F6CC wds:Q34480689-6A064DE3-96A6-4F35-BD4B-F1FD803AF076 wds:Q34480689-6A1E05EE-1BE6-4907-9FCD-CCDC8326F7C2 wds:Q34480689-7BF049D8-8B01-4AC1-A61A-6902B5643085 wds:Q34480689-5E1B8C3D-06E4-46B8-9017-A938DE7A402D wds:Q34480689-600BDBDB-EDF3-4F45-A565-047CAA15B0DB wds:Q34480689-62334616-5DD3-4C67-B1BF-E3933DB9ADFE wds:Q34480689-68E8000C-59B6-44A3-9B05-51D11E94D255 wds:Q34480689-4C9FE967-67E5-4C1E-92E4-15E87871CDBA wds:Q34480689-589DCC13-19D8-4C38-B565-D5A94E79C6DB wds:Q34480689-3B2B0F09-A7D4-4012-9BB4-6307A9E9FCAD wds:Q34480689-3DC24400-E968-4F61-B609-84DAAEA6E8BA wds:Q34480689-3A2EA83E-0076-40F7-B8B0-6FF438AA8200 wds:Q34480689-28384437-5D6B-437D-890E-F728DC75575D wds:Q34480689-2F0EB40D-FE47-4BBD-A743-5FCBD4D02CC0 wds:Q34480689-15C70F3B-A9E0-456D-A1AE-F3B312833B3A wds:Q34480689-1E9D0511-EB21-4E51-8276-F18D41AA6EA5 wds:Q34480689-04FADFF2-FB82-4EFD-81F8-93734FA473CA wds:Q34480689-058E0E7A-7C4D-472E-ABE9-888CFA484C27 wds:Q34480689-EA8573EE-C84B-49BB-B796-B11176152104 wds:Q34480689-F69CBF04-B991-4FD9-9986-D5772314AA8B wds:Q34480689-E1642B38-C649-495E-93CF-200E552042CB wds:Q34480689-E62C0FBA-68DE-46FA-8FAA-21864E50A68D wds:Q34480689-E6826BF3-D2CF-4A56-9F40-9BCE96753E0C wds:Q34480689-D897C3AD-24E4-4C4F-807C-8B6CA8B13718 wds:Q34480689-D96D6B1C-BE1D-4614-955E-88BE994E992C wds:Q34480689-DB2E4162-703A-4251-9500-80D3B32CEA2F wds:Q34480689-CD62325A-4951-488E-AD7B-3D45D29388FC wds:Q34480689-BD1BE215-E915-40CF-BFBA-702BFCA9729E wds:Q34480689-BFF95828-8576-4BA6-949C-76F290A0EC4E wds:Q34480689-C235F39D-E038-4D13-9A72-BA2596C4A670 wds:Q34480689-A3A3C46B-D981-4818-8FA6-36D518273AE5 wds:Q34480689-B772ECA6-B487-432B-B2B7-4F7057D18884
wdt:P2860
wd:Q74114483 wd:Q31154294 wd:Q29615708 wd:Q27824850 wd:Q33447142 wd:Q33731698 wd:Q37221453 wd:Q37481863 wd:Q48271471 wd:Q46942082 wd:Q44781447 wd:Q44669178 wd:Q44093928 wd:Q39850353 wd:Q33370229 wd:Q33382596 wd:Q36621800 wd:Q36900428 wd:Q44256659 wd:Q43742602 wd:Q37036914 wd:Q40789890 wd:Q35800541 wd:Q40349190 wd:Q33407127 wd:Q34673567 wd:Q48264845 wd:Q34350623 wd:Q29617568 wd:Q48536258 wd:Q39852633 wd:Q31148416 wd:Q36692599 wd:Q34132643 wd:Q44393459 wd:Q35688316 wd:Q48739136 wd:Q28308193 wd:Q37594926 wd:Q30584392
p:P2093
wds:Q34480689-0D4D3D8D-63A4-4578-AB6C-FFF1673CFAC5 wds:Q34480689-44D4A55B-4FB2-4472-A094-C5668308459C
wdt:P2093
Alyssa Mathe Marta Hamilton
rdfs:label
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
skos:prefLabel
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
schema:name
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
p:P50
wds:Q34480689-171CC520-FB56-4679-B014-D12BE3ABF592 wds:Q34480689-2FDE142C-0808-4357-B907-4806DDCFFFFB wds:Q34480689-31B0DAE3-903E-4DA1-9190-CBD590585C4D wds:Q34480689-32F34CC6-EF55-4A40-B029-AD2CC142CE90 wds:Q34480689-33FF8BC0-D0B2-4F43-B90A-DD4A48634BCE wds:Q34480689-84852DC4-61EA-4069-85BF-C72D386843D9 wds:Q34480689-BA0F75FD-E211-4AE9-A778-3F48119E5542 wds:Q34480689-C896A16F-8881-4FDA-A477-1FA76F58FE43 wds:Q34480689-D4471576-81A9-41CF-9B6F-699E63B37B91 wds:Q34480689-E226AF49-4AAC-46C5-B074-BD9C9DE5AEAB wds:Q34480689-F5F14D82-8BB7-4183-9D59-4A7CB16222D0
wdt:P50
wd:Q114444381 wd:Q86911163 wd:Q112381232 wd:Q73536038 wd:Q96144364 wd:Q116793246 wd:Q114574412 wd:Q73536128 wd:Q73570385 wd:Q92482497 wd:Q73422966
p:P1476
wds:Q34480689-E99DE6D1-C28E-4079-9822-CF7088BB9DDF
wdt:P1476
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
p:P304
wds:Q34480689-82593C62-A5DE-4F3D-ACA3-0472E1014089
wdt:P304
1300-1310
p:P31
wds:Q34480689-4FD86D68-3A7E-4AED-8258-2CEA806B5631
wdt:P31
wd:Q13442814
p:P921
wds:Q34480689-43829CDC-F45D-4A32-A6A3-04D14DFCD67A wds:Q34480689-7C05761D-4B55-47C9-8C74-D1A7470CDD4E wds:Q34480689-0C33E5F7-8B1B-46A8-B555-E14EBDE54403
wdt:P921
wd:Q42824440 wd:Q413299 wd:Q181600
p:P698
wds:Q34480689-058AD337-5531-47F9-9B7A-42D8537BAF7B
wdtn:P698
n11:20716591
wdt:P698
20716591
p:P1433
wds:Q34480689-BEC8EF84-209D-498A-A13B-1A56D1AC3070
wdt:P1433
wd:Q15724471
p:P433
wds:Q34480689-A54D9E7E-2689-4A98-9BC0-66151B25E427
p:P478
wds:Q34480689-2C78ACA5-4939-4EE4-B31E-7B3F8B8B2932
wdt:P433
12
wdt:P478
12
p:P356
wds:Q34480689-D1B0B16B-F281-4884-81BC-7322AB3341FC
wdtn:P356
n10:NOQ099
wdt:P356
10.1093/NEUONC/NOQ099
p:P5875
wds:Q34480689-57741ED1-1EA9-41A6-B26E-B728183DFC55
wdt:P5875
45694620
p:P932
wds:Q34480689-CA2E73D5-9857-449E-850C-E67B90F7405E
wdt:P932
3018944